Cue Biopharma (CUE) EPS (Weighted Average and Diluted) (2021 - 2025)
Cue Biopharma (CUE) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.03 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 130.0% to $0.03 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.3 through Dec 2025, up 58.33% year-over-year, with the annual reading at -$0.28 for FY2025, 61.11% up from the prior year.
- EPS (Weighted Average and Diluted) hit $0.03 in Q4 2025 for Cue Biopharma, up from -$0.07 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.03 in Q4 2025 to a low of -$0.44 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.24 across 5 years, with a median of -$0.25 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 52.0% in 2022 and later soared 130.0% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then plummeted by 52.0% to -$0.38 in 2022, then rose by 23.68% to -$0.29 in 2023, then soared by 65.52% to -$0.1 in 2024, then skyrocketed by 130.0% to $0.03 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for CUE at $0.03 in Q4 2025, -$0.07 in Q3 2025, and -$0.09 in Q2 2025.